Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood
The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
Rationale No studies to date have directly compared the tolerability and efficacy of smoked marijuana and oral dronabinol in HIV(+) marijuana smokers. Objectives The aim of this study was to compare dronabinol (0, 10, 20, 30 mg p.o.) and marijuana [0.0, 1.8, 2.8, 3.9% Delta(9)-tetrahydrocannabinol (THC)] in two samples of HIV(+) marijuana smokers: those with (n=15) and those without (n=15) a clinically significant loss of muscle mass ( Methods Mood, physical symptoms, self-selected food intake, cardiovascular data, and cognitive task performance were measured before and repeatedly after dronabinol and marijuana administration in eight 7-h sessions. Marijuana and dronabinol were administered in randomized order using a within-subject, staggered, double-dummy design. Results As compared to placebo, (1) marijuana (1.8, 2.8, 3.9% THC) and the lower dronabinol doses (10, 20 mg) were well tolerated (e.g., few physical symptoms, significant increases in ratings of "good drug effect") in both groups of participants; the highest dose of dronabinol (30 mg) was poorly tolerated in a subset of participants; (2) marijuana and dronabinol significantly increased caloric intake in the low bioelectrical impedance analysis (BIA) group but not in the normal BIA group; and (3) drug effects on cognitive performance were minor. Conclusions These data suggest that for experienced marijuana smokers with clinically significant muscle mass loss, both dronabinol (at acute doses at least four to eight t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Neuropsychological Performance in Long-term Cannabis Users
Pope, H. G., Gruber, A. J., Hudson, J. I., Huestis, M. A., & Yurgelun-Todd, D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.909 · Cited by 655
Prevalence of Marijuana Use Disorders in the United States: 1991-1992 and 2001-2002
Compton, W. M., Grant, B. F., Colliver, J. D., Glantz, M. D., & Stinson, F. S. (2004) · JAMA · doi:10.1001/jama.291.17.2114 · Cited by 537
Pulmonary Hazards of Smoking Marijuana as Compared with Tobacco
WU, T.-C., Tashkin, D. P., Djahed, B., & Rose, J. E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802113180603 · Cited by 521
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
Beal, J. E., Olson, R., Laubenstein, L., Morales, J. O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T. F., & Shepard, K. V. (1995) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(94)00117-4 · Cited by 504 · cited 3×
“For example, in non-marijuana smokers, much lower doses of dronabinol (e.g., 2.5 mg) produced confusion and anxiety ( Beal et al. 1995; Timpone et al. 1997).”
BackgroundInfluentialKotler, D., Burastero, S., Wang, J., & Pierson, R. (1996) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/64.3.489s · Cited by 472 · cited 1×
“Those less than 90% of ideal body cell mass based on HIV-validated norms were placed in the low BIA group (Kotler et al. 1996).”
MethodMarijuana and medicine: assessing the science base
(1999) · Choice Reviews Online · doi:10.5860/choice.37-2206 · Cited by 410
Agurell, S., Halldin, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., & Hollister, L. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06861-9 · Cited by 406
Abstinence symptoms following smoked marijuana in humans
Haney, M., Ward, A. S., Comer, S. D., Foltin, R. W., & Fischman, M. W. (1999) · Psychopharmacology · doi:10.1007/s002130050849 · Cited by 353
Self-citationEffects of Acute Smoked Marijuana on Complex Cognitive Performance
Hart, C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00273-1 · Cited by 271
Cited by
The Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
Hazekamp, A., Ware, M. A., Muller-Vahl, K. R., Abrams, D., & Grotenhermen, F. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.805976 · Cited by 238
Colorado Family Physicians' Attitudes Toward Medical Marijuana
Kondrad, E., & Reid, A. (2013) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2013.01.120089 · Cited by 221
Baron, E. P. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12570 · Cited by 206
Cooper, Z. D., & Haney, M. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.01.023 · Cited by 193
“In the past, heart rate has been reported to reliably increase as a function of cannabis strength (Haney, 2007; Haney et al., 2005; Hart et al., 2005; McDonald et al., 2003), and to be a predictor of marijuana intoxication.”
BackgroundSelf-citationTasty THC: Promises and Challenges of Cannabis Edibles
International, R., Barrus, D., Capogrossi, K., Cates, S., Gourdet, C., Peiper, N., Novak, S., Lefever, T., & Wiley, J. (2016) · doi:10.3768/rtipress.2016.op.0035.1611 · Cited by 194
Cannabinoids and appetite: food craving and food pleasure
Kirkham, T. C. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782810 · Cited by 189
“It was suggested that the specific alleles do not necessarily increase an individual’s susceptibility to developing anorexia nervosa, but may modify the form of its expression.”
BackgroundDronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric Intake, Mood, and Sleep
Haney, M., Gunderson, E. W., Rabkin, J., Hart, C. L., Vosburg, S. K., Comer, S. D., & Foltin, R. W. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31811ed205 · Cited by 184
Self-citationAggarwal, P., Carter, M., Sullivan, M., ZumBrunnen, P., Morrill, P., & Mayer, P. (2018) · Journal of Opioid Management · doi:10.5055/jom.2009.0016 · Cited by 184
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Systematic review and meta‐analysis of cannabinoids in palliative medicine
Mücke, M., Weier, M., Carter, C., Copeland, J., Degenhardt, L., Cuhls, H., Radbruch, L., Häuser, W., & Conrad, R. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12273 · Cited by 158
Riedel, G., Fadda, P., McKillop‐Smith, S., Pertwee, R. G., Platt, B., & Robinson, L. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00107.x · Cited by 146
“The appetite enhancing properties of exogenously administered cannabinoids (smoking marijuana or administration of D(9)-THC in the synthetic form of Dronabinol) are part of the therapy for weight loss in patients suffering from HIV and cancer (Timpone et al, 1997; Haney et al. 2005; Walsh et al, 2005).”
BackgroundThe medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS
Lutge, E. E., Gray, A., & Siegfried, N. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005175.pub3 · Cited by 131
Kramer, J. L. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21260 · Cited by 130
“In placebo-controlled studies of HIV-positive chronic marijuana smokers, smoking marijuana led to an increase in food intake.(106,107) This may be mediated through increases in the hormones ghrelin and leptin, as well as decreases in peptide tyrosine tyrosine, which help regulate appetite (Table 3).”
BackgroundResultRole of cannabis in digestive disorders
Goyal, H., Singla, U., Gupta, U., & May, E. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000779 · Cited by 119
The marijuana withdrawal syndrome: Diagnosis and treatment
Haney, M. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0036-1 · Cited by 118
Self-citationReview on clinical studies with cannabis and cannabinoids 2005-2009
Hazekamp, A., & Grotenhermen, F. (2010) · Cited by 122
Effects of cannabis on cognitive function in patients with multiple sclerosis
Honarmand, K., Tierney, M. C., O'Connor, P., & Feinstein, A. (2011) · Neurology · doi:10.1212/wnl.0b013e318212ab0c · Cited by 99
“Randomized trials examining the effects of smoked cannabis have also reported increased caloric intake in HIV-positive patients (Haney et al., 2005; Haney, Rabkin, Gunderson, & Foltin, 2007).”
BackgroundBelendiuk, K. A., Baldini, L., & Bonn‐Miller, M. O. (2015) · Addiction Science & Clinical Practice · doi:10.1186/s13722-015-0032-7 · Cited by 109
“Furthermore, while some studies have no participant withdrawal due to adverse events [21,70,71], others reported treatment-limiting adverse events [26,72,73].”
BackgroundEstradiol signaling in the regulation of reproduction and energy balance
Sinchak, K., & Wagner, E. J. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.08.004 · Cited by 109
“in ameliorating the cachexia associated with HIV/AIDS and cancer (Haney et al., 2005; Inui, 2002).”
BackgroundSex-dependent effects of cannabis-induced analgesia
Cooper, Z. D., & Haney, M. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.08.001 · Cited by 108
“Participants were also asked to indicate whether they thought the cannabis was ‘placebo’ or ‘active’ (Haney et al., 2005).”
BackgroundSelf-citationOpportunities for cannabis in supportive care in cancer
Kleckner, A. S., Kleckner, I. R., Kamen, C. S., Tejani, M. A., Janelsins, M. C., Morrow, G. R., & Peppone, L. J. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919866362 · Cited by 105
Onaivi, E. S., Carpio, O., Ishiguro, H., Schanz, N., Uhl, G. R., & Benno, R. H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1432.035 · Cited by 91
Phytochemicals in the Control of Human Appetite and Body Weight
Tucci, S. A. (2010) · Pharmaceuticals · doi:10.3390/ph3030748 · Cited by 93
“[101–107].”
Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers
Cooper, Z. D., Comer, S. D., & Haney, M. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.97 · Cited by 97
Self-citationBedi, G., Cooper, Z. D., & Haney, M. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00427.x · Cited by 83
“Conversely, peak effects for both doses of dronabinol occurred 90 minutes after capsule administration, consistent with earlier findings (e.g. Haney et al. 2005).”
ResultSelf-citationA User’s Guide to Cannabinoid Therapies in Oncology
Maida, V., & Daeninck, P. J. (2016) · Current Oncology · doi:10.3747/co.23.3487 · Cited by 90
Bedi, G., Foltin, R. W., Gunderson, E. W., Rabkin, J., Hart, C. L., Comer, S. D., Vosburg, S. K., & Haney, M. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1995-4 · Cited by 77
“One outpatient study we conducted indicated that single dronabinol doses increase caloric intake over a seven-hour period only in individuals with significant muscle loss (Haney et al. 2005).”
BackgroundMethodResultInfluentialSelf-citationMedical marijuana and the developing role of the pharmacist
Seamon, M. J., Fass, J. A., Maniscalco-Feichtl, M., & Abu-Shraie, N. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060471 · Cited by 81
“Nevertheless, marijuana use may lead to increased food intake in patients with HIV who have low muscle mass and is often used safely in a subset of this population.(63) Marijuana may exacerbate psychiatric disorders in patients with schizophrenia, psychosis, bipolar disorder, depression, eating disorders, or panic and…”
BackgroundMedicinal Uses of Marijuana and Cannabinoids
Grotenhermen, F., & Müller‐Vahl, K. (2016) · Critical Reviews in Plant Sciences · doi:10.1080/07352689.2016.1265360 · Cited by 88
“%) on food intake in 30 HIV positive cannabis smokers in eight 7-h sessions (Haney et al., 2005).”
BackgroundTargeting Intermediary Metabolism in the Hypothalamus as a Mechanism to Regulate Appetite
Lopaschuk, G. D., Ussher, J. R., & Jaswal, J. S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002428 · Cited by 81
Patterns and Correlates of Cannabis Use among Individuals with HIV/AIDS in Maritime Canada
Harris, G. E., Dupuis, L., Mugford, G. J., Johnston, L. D., Haase, D. A., Page, G., Haldane, H., Harris, N. M., Midodzi, W. K., & Dow, G. (2014) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2014/301713 · Cited by 65
Therapeutic potential of medicinal marijuana: an educational primer for health care professionals
Mouhamed, Y., Vishnyakov, A., Qorri, B., Sambi, M., Frank, S. M. S., Nowierski, C., Lamba, A., Bhatti, U., & Szewczuk, M. R. (2018) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s158592 · Cited by 64
Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature
Inglet, S., Winter, B., Yost, S. E., Entringer, S., Lian, A., Biksacky, M., Pitt, R. D., & Mortensen, W. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020930189 · Cited by 61
Sex differences in cannabinoid-regulated biology: A focus on energy homeostasis
Wagner, E. J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.01.003 · Cited by 61
“…it comes in the form of case reports, epidemiological studies or randomized, double blind, placebo controlled investigations, the overwhelming majority of the study participants were male (Beal et al., 1995; Haney et al., 2005; Nelson et al., 1994; Sacks et al., 1990; Woolridge et al., 2005).”
BackgroundMedical Marijuana for Digestive Disorders: High Time to Prescribe?
Gerich, M. E., Isfort, R. W., Brimhall, B. B., & Siegel, C. A. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.245 · Cited by 57
Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS
Badowski, M. E., & Pérez, S. E. (2016) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s81420 · Cited by 55
“0001) (Table 1).(24) It is interesting to note that this effect occurred only in subjects with a normal bioelectrical impedance analysis and measurement of body fat in relation to lean body mass.”
Marijuana Effectiveness as an HIV Self-Care Strategy
Corless, I. B., Lindgren, T. G., Holzemer, W. L., Robinson, L. L., Moezzi, S., Kirksey, K. M., Coleman, C. L., Tsai, Y., Eller, L. S., Hamilton, M. J., et al. (2009) · Clinical Nursing Research · doi:10.1177/1054773809334958 · Cited by 50
Murphy, T., & Foll, B. L. (2020) · Biomolecules · doi:10.3390/biom10060855 · Cited by 53
“…Within-subject HIV-positive cannabis users (n = 7) Dronabinol PartialAgonist Oral (20 mg/day 2 days, 40 mg/day 14 days) 16 days No change Haney et al., 2005 [23] Double-blinded, Within-subject HIV-positive cannabis users (n = 30) Dronabinol PartialAgonist Oral (10, 20, 30 mg/day) 3–4…”
Sansone, R. A., & Sansone, L. A. (2014) · Europe PMC (PubMed Central) · Cited by 50
Diaz, S., Farhang, B., Hoien, J., Stahlman, M., Adatia, N., Cox, J. M., & Wagner, E. J. (2009) · Neuroendocrinology · doi:10.1159/000191646 · Cited by 50
A Review of Cannabis in Chronic Kidney Disease Symptom Management
Ho, C., Martinusen, D. J., & Lo, C. (2019) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358119828391 · Cited by 55
Estrogen rapidly attenuates cannabinoid-induced changes in energy homeostasis
Kellert, B., Nguyen, M. C., Nguyen, C., Nguyen, Q. H., & Wagner, E. J. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.001 · Cited by 47
“…(Williams and Kirkham, 2002) and guinea pigs (Ho et al., 2007; Diaz et al., 2009), and in humans dronabinol and marijuana have been utilized as pharmacotherapeutic adjuncts to ameliorate body wasting in cancer (Walsh et al., 2005) and HIV/AIDS (Woolridge et al., 2005; Haney et al., 2005) patients.”
Jarrett, M. M., Scantlebury, J., & Parker, L. A. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.10.003 · Cited by 46
Spanagel, R., & Bilbao, A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108680 · Cited by 43
“…et al., 1981; Ungerleider et al., 1985; Chan et al., 1987; Lane et al., 1990; Killestein et al., 2002; Bredt et al., 2002; Abrams et al., 2003; Haney et al., 2004, 2005; 2007, 2008; Attal et al., 2004; D’Souza et al., 2005; Budney et al., 2007; Bedi et al., 2010; Klooker et al., 2011; Zajicek…”
Substance-related disorders: A review of prevalence and correlates among patients with chronic pain
Martel, M. O., Shir, Y., & Ware, M. A. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.032 · Cited by 49
Mücke, M., Carter, C., Cuhls, H., Prüß, M. S., Radbruch, L., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0085-2 · Cited by 41
Sex differences in the cannabinoid regulation of energy homeostasis
Farhang, B., Diaz, S. V., Tang, S. L., & Wagner, E. J. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.04.007 · Cited by 41
“, 2005) and HIV/AIDS (Woolridge et al., 2005; Haney et al., 2005), as well as with irretractable chronic pain (Lynch et al.”
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
Fernández‐Ruíz, J., Galve‐Roperh, I., Sagredo, O., & Guzmán, M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.013 · Cited by 39
Borgquist, A., Meza, C., & Wagner, E. J. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00421.2014 · Cited by 36
“Most of the clinical studies touting the ability of cannabinoids to stimulate appetite in cachexic patients used experimental subjects that were almost exclusively male (25, 52, 66, 75, 80).”
BackgroundThe Place of Cannabinoids in the Treatment of Gynecological Pain
Sinclair, J., Abbott, J. A., Proudfoot, A., & Armour, M. (2023) · Drugs · doi:10.1007/s40265-023-01951-z · Cited by 37
Translational models of cannabinoid vapor exposure in laboratory animals
Moore, C. F., Stiltner, J. W., Davis, C. M., & Weerts, E. M. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000592 · Cited by 32
“dronabinol, marinol) are FDA-approved to treat or prevent nausea and vomiting in cancer patients (Fraguas-Sanchez and TorresSuarez, 2018), and to increase appetite and reduce weight loss in people with wasting disease associated with AIDS (Haney et al., 2005; Badowski and Perez, 2016).”
BackgroundMedical marijuana in pediatric oncology: A review of the evidence and implications for practice
Ananth, P. J., Reed-Weston, A. E., & Wolfe, J. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26826 · Cited by 33
Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders
Ishiguro, H., Kibret, B. G., Horiuchi, Y., & Onaivi, E. S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.828895 · Cited by 31
Marijuana’s acute effects on cognitive bias for affective and marijuana cues.
Metrik, J., Aston, E. R., Kahler, C. W., Rohsenow, D. J., McGeary, J. E., & Knopik, V. S. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000030 · Cited by 34
“Subjective effects of marijuana were assessed with the Addiction Research Center Inventory-Marijuana scale (ARCI-M; Chait et al., 1985; Martin et al., 1971) and with the 0–100 visual analogue scale (VAS) Marijuana Rating Form (Haney et al., 2005).”
BackgroundMethodWashburn, N., Borgquist, A., Wang, K., Jeffery, G. S., Kelly, M. J., & Wagner, E. J. (2012) · Neuroendocrinology · doi:10.1159/000338669 · Cited by 27
Mela, V., Vargas, A., Meza, C., Kachani, M., & Wagner, E. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.014 · Cited by 27
A pharmacological characterization of Cannabis sativa chemovar extracts
Devsi, A., Kiyota, B., Ouellette, T., Hegle, A. P., Rivera-Acevedo, R. E., Wong, J., Dong, Y., Pugsley, M. K., & Fung, T. (2020) · Journal of Cannabis Research · doi:10.1186/s42238-020-00026-0 · Cited by 26
New Frontiers in Endocrinology of Eating Disorders
Monteleone, P. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_87 · Cited by 34
Ayoub, S. M., Holloway, B. M., Miranda, A. H., Roberts, B. Z., Young, J. W., Minassian, A., & Ellis, R. J. (2024) · Current HIV/AIDS Reports · doi:10.1007/s11904-024-00698-w · Cited by 24
“In one study, acutely administered mid-to-high doses of dronabinol (20–30 mg), but not lower dronabinol doses or low-potency (0–3.9% THC) smoked cannabis, impaired divided attention and psychomotor speed in PWH [90].”
InfluentialCannabinoids, cannabinoid receptors and tinnitus
Smith, P. F., & Zheng, Y. (2015) · Hearing Research · doi:10.1016/j.heares.2015.09.014 · Cited by 26
Cannabis constituents modulate ∆9-tetrahydrocannabinol-induced hyperphagia in rats
Farrimond, J. A., Hill, A. J., Whalley, B. J., & Williams, C. M. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1821-z · Cited by 24
“There is, therefore, a strong interest in the application of cannabinoid therapeutics to stimulate appetite and reduce side effects of cancer chemotherapy treatment and in AIDS wasting syndrome (Haney et al. 2005).”
BackgroundQuais são e pra que servem os medicamentos à base de Cannabis?
Pamplona, F. A. (2014) · Revista da Biologia · doi:10.7594/revbio.13.01.05 · Cited by 20
“Por outro lado, na Holanda, desde 2003 uma linhagem padronizada de Cannabis conhecida como Bedrocan® era fornecida por farmácias autorizadas e inicialmente indicada para vômitos associados à quimioterapia, perda de peso e dor neuropática associado ao HIV/AIDS (Haney et al., 2005, Ellis et al., 2009).”
BackgroundTherapeutic Applications for Agents that Act at CB1 and CB2 Receptors
Pertwee, R. G., & Thomas, A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-503-9_13 · Cited by 24
“Further evidence that dronabinol can stimulate food intake in HIV patients was obtained recently in a placebo-controlled study in which single, oral administration of this drug (10, 20, or 30 mg) was found to stimulate caloric intake in experienced cannabis smokers with HIV [160].”
BackgroundWu, M. M., Zhang, X., Asher, M. J., & Thayer, S. A. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146467 · Cited by 21
Reciprocal Influences of HIV and Cannabinoids on the Brain and Cognitive Function
Towe, S. L., Meade, C. S., Cloak, C. C., Bell, R. P., Baptiste, J., & Chang, L. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09921-y · Cited by 19
“Persons with HIV report using cannabis for relief of symptoms associated with HIV, including pain, nausea, loss of appetite, and anxious or depressed mood (Abrams et al. 2007; D’Souza et al. 2012; Haney et al. 2007; Haney et al. 2005; Prentiss et al. 2004).”
BackgroundNausea and vomiting in HIV: a symptom review
Chubineh, S., & McGowan, J. P. (2008) · International Journal of STD & AIDS · doi:10.1258/ijsa.2008.008244 · Cited by 18
Cannabinoid drugs: will they relieve or exacerbate tinnitus?
Zheng, Y., & Smith, P. F. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000631 · Cited by 18
Mini-review: The therapeutic role of cannabinoids in neuroHIV
Yadav-Samudrala, B. J., & Fitting, S. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135717 · Cited by 21
“cannabis use has been investigated and found to affect various biological processes, including cognitive performance [58, 228, 233], appetite [63, 90, 222], mood [16, 18], and neuropathic pain [2, 73, 167].”
Cannabinoids in Eating Disorders and Obesity
Árias, F. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0018-x · Cited by 20
Nabilone administration in refractory chronic diarrhea: a case series
Pellesi, L., Verga, M. C., Maria, N. D., Villa, E., Pini, L. A., & Guérzoni, S. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1024-y · Cited by 16
Hazekamp, A., & Pappas, G. J. (2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199662685.003.0017 · Cited by 28
Cannabinoids for Pain Management
Thaler, A., Gupta, A., & Cohen, S. P. (2011) · Advances in psychosomatic medicine · doi:10.1159/000324070 · Cited by 15
Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative Review
Worth, H., O’Hara, D. V., Agarwal, N., Collister, D., Brennan, F., & Smyth, B. J. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11560821 · Cited by 15
A prospective observational study of problematic oral cannabinoid use
Ware, M. A., Martel, M. O., Jovey, R. D., Lynch, M. E., & Singer, J. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4811-6 · Cited by 15
“…7 Department of Anesthesia, Pain Medicine, and Perioperative Care, Dalhousie University, Halifax, Canada 8 School of Population and Public Health, University of British Columbia, Vancouver, Canada 2007; Haney et al. 2005, 2007), and multiple sclerosis (Collin et al. 2010; Notcutt et al. 2012).”
Lee, J. T., Peetluk, L. S., Kipp, A. M., Logan, J., Shepherd, B. E., Koethe, J. R., Turner, M. M., Bebawy, S. S., Sterling, T. R., & Hulgan, T. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02430-x · Cited by 13
Kopcho, S., McDew‐White, M., Naushad, W., Mohan, M., & Okeoma, C. M. (2023) · Viruses · doi:10.3390/v15030623 · Cited by 12
“Cannabis use is common among people living with HIV (PLWH), who often use it to manage disease symptoms [11,12].”
BackgroundEpidemiology of Psychopathology in HIV
Wainberg, M. L., McKinnon, K. M., & Cournos, F. (2014) · Wiley eBooks · doi:10.1002/9781118339503.ch1 · Cited by 11
Okafor, C. N., Plankey, M. W., Goodman‐Meza, D., Li, M. J., Bautista, K. J., Bolívar, H., Tien, P. C., Brown, T. T., & SHOPTAW, S. J. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107935 · Cited by 11
“Stimulation of CBR1 by THC increases appetite and promotes caloric consumption (Foltin et al., 1988; Haney et al., 2005; Hart et al., 2002), suggesting that regular marijuana use may promote weight gain and concomitant higher body mass index (BMI), an established risk factor for type 2 diabetes (Ganz et al.”
BackgroundMurray, C. H., Haney, M., Foltin, R. W., Manubay, J. M., Bedi, G., & Cooper, Z. D. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109757 · Cited by 9
Self-citationCannabis and Cannabinoids on Treatment of Inflammation: A Patent Review
Menezes, P. M. N., Pereira, E. C. V., Silva, M. E. G. D. C., da Silva, B. A. O., Filho, L. A. M. D. S. D., Araújo, T. C. D. L., Lima, K. S. B., Silva, F. S., & Rolim, L. A. (2019) · Recent Patents on Biotechnology · doi:10.2174/1872208313666190618124345 · Cited by 12
Therapeutic Cannabis Use in Kidney Disease: A Survey of Canadian Nephrologists
Gitau, K., Howe, H. S., Ginsberg, L., Perl, J. M., & Ailon, J. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100453 · Cited by 10
O’Neill, T. J., Raboud, J., Tinmouth, J., Rourke, S. B., Gardner, S. L., Cooper, C., Rueda, S., Hart, T. A., Rachlis, A., Burchell, A. N., et al. (2016) · AIDS Care · doi:10.1080/09540121.2016.1210076 · Cited by 8
“Similar to our findings, increased weight gain is common with current marijuana use (Haney et al., 2005), while its use has not been shown to modulate abdominal pain or bloating (Gerich, Isfort, Brimhall, & Siegel, 2015).”
ResultAppetite and food intake: a human experimental perspective
Yeomans, M. R., & Bertenshaw, E. J. (2008) · Figshare · Cited by 9
The novel cannabinoid CB1 receptor agonist AM11101 increases food intake in female rats
Ogden, S. B., Malamas, M. S., Makriyannis, A., & Eckel, L. A. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14797 · Cited by 8
Ayoub, S. M., Vemuri, S., Hoang, E. B., Jha, N. A., Minassian, A., & Young, J. W. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.030 · Cited by 8
Cannabis for Symptom Control #279
Aggarwal, S. K., & Blinderman, C. D. (2014) · Journal of Palliative Medicine · doi:10.1089/jpm.2014.9431 · Cited by 9
Mücke, M., Carter, C., Cuhls, H., Prüß, M. S., Radbruch, L., & Häuser, W. (2016) · Der Schmerz · Cited by 7
Therapeutic uses of Cannabis sativa L. Current state and future perspectives
Fraguas‐Sánchez, A. I., & Torres‐Suárez, A. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89867-6.00010-x · Cited by 7
Amedei, A., & Niccolai, E. (2014) · Wiley eBooks · doi:10.1002/9781118876015.ch4 · Cited by 10
Cannabis use and obesity-traits: A Mendelian randomization study
Alayash, Z., Nolde, M., Meisinger, C., Baurecht, H., & Baumeister, S. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108863 · Cited by 7
Appetite and Food Intake: A Human Experimental Perspective
Yeomans, M. R., & Bertenshaw, E. J. (2008) · CRC Press eBooks · doi:10.1201/9781420047844.ch4 · Cited by 8
Endocannabinoids in the aetiopathology of obesity – Central mechanisms
Kirkham, T. C., & Rogers, E. K. (2010) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2010.12.003 · Cited by 5
Cannabis, Cannabinoids and Tinnitus
Smith, P. F., & Zheng, Y. (2016) · doi:10.17303/jpdm.2014.1.201 · Cited by 3
Are cannabinoids effective for HIV wasting syndrome?
Núñez, A., Núñez, C., Corsi, Ó., & Gabriel Rada, G. (2017) · Medwave · doi:10.5867/medwave.2017.09.7107 · Cited by 3
Caring for Patients Using Medical Marijuana
Russell, K. A. (2019) · Journal of Nursing Regulation · doi:10.1016/s2155-8256(19)30148-6 · Cited by 5
Should gastroenterologists prescribe cannabis? The highs, the lows and the unknowns
Samuel, S. B., Michael, M., & Tadros, M. S. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i18.4210 · Cited by 2
Ho, J., Harrison, J., & Battistella, M. (2024) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241274002 · Cited by 3
[Dietary intakes in a group of marihuana smoking patients].
de Luis, D. A., Armentia, A., Muñoz, P., Dueñas‐Laita, A., Martín, B., la Fuente, B. D., & Izaola, O. (2010) · PubMed · Cited by 2
Wirksamkeit, Verträglichkeit und Sicherheit von medizinischem Cannabis
Hoch, E., Schneider, M., von Keller, R., Bonnet, U., Falkai, P., Hasan, A., Häuser, W., Hinz, B., Jakob, L., Kabisch, J., et al. (2018) · Springer eBooks · doi:10.1007/978-3-662-57291-7_4 · Cited by 2
Metadata
- Authors
- Haney, M., Rabkin, J., Gunderson, E., & Foltin, R. W.
- Affiliations
- New York State Psychiatric Institute (US)
- Corresponding author
- Haney, Margaret
- Venue
- Psychopharmacology
- Published
- 2005-03-19
- Volume
- 181
- Issue
- 1
- Pages
- 170-178
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2056047771
- Cited by
- 126
- References
- 49
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 12 · 2021: 4 · 2020: 8 · 2019: 9 · 2018: 7 · 2017: 4 · 2016: 14 · 2015: 6 · 2014: 11 · 2013: 6 · 2012: 4
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (DA-09236, R01DA012698, P50DA009236, DA12698)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- dronabinol, cannabis smoking, HIV, AIDS wasting, muscle mass loss, energy intake, dietary intake, mood, drug tolerability, cognitive performance, delta-9-tetrahydrocannabinol, bioelectrical impedance analysis, body cell mass
- MeSH terms
- Adult, Affect, Energy Intake, Capsules, Diarrhea, Dose-Response Relationship, Drug, Eating, Female, Headache, Heart Rate, HIV Seropositivity, Humans, Hunger, Male, Marijuana Smoking, Nausea, Psychotropic Drugs, Surveys and Questionnaires, Mental Recall, Satiety Response, Task Performance and Analysis, Dronabinol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.